Cells work like tiny machines in the body. They are always working to break down, repair, recycle, and build the body at its most fundamental level. And just as real towns and cities need to be cleaned and cleared of waste, cells also need a way to clear out proteins that are damaged or no longer effective.
If the damaged or non-effective proteins in the body are not cleared out, they can cause a lot of damage, and at the top of that damage list is cancer. This is where Pevonedistat NAE Inhibitor comes into the picture. This is a special drug that can inhibit the progress of cancer-causing proteins. Pevonedistat is great at blocking how cancers grow through the spread or buildup of proteins.
Pevonedistat Explained
In the human body, it is normal for cells to tag damaged or old proteins for breakdown, and the marker is called ubiquitin. NAE, which is a NEDD8-Activating Enzyme, starts the same tagging process as explained above, and it is called neddylation. Here, the NEDD8 protein becomes attached to other proteins, chief of which are those in the cullin-RING ligase family.
Their primary function is to mark those proteins that require destruction and then to dispose of them. However, this system can become faulty when cancer cells take it over so the system is unable to prevent them from rapidly multiplying. They do this by causing the neddylation pathway to become overactivated, which then enhances the survival and spread of tumors.
When NAE is targeted, it can no longer mark proteins that should be disposed of, which leads to a buildup that causes the cancer cells to self-destruct or shut down. This is what Pevonedistat, an experimental cancer treatment, does. It inhibits NAE, throwing a wrench in the entire process, thereby causing the cancer cells stress and causing them to collapse while normal cells pause and recover.
How Does It Work?
It is common knowledge that cancer cells divide very rapidly, which is why it is important that systems that control cancer-causing proteins are up and running to keep this speed in check. Otherwise, cells become vulnerable to damage that could have been avoided.
For those systems to work, NAE must efficiently start the neddylation process. However, Pevonedistat (MLN4924) NAE Inhibitor shuts it down. This is a small molecule that goes inside cells and binds itself to NAE to form a “fake” system that stops the NEDD8 enzyme from working as it should. AMP, which is a natural molecule, inspires this process but in Pevonedistat, it is worked on to make it more effective than usual.
Inside them, Pevonedistat starts to work by interfering with the neddylation process. As a result, the cullin-RING ligases cannot work, which leads to a buildup of substrates, such as p27 and CDT1. The disruption can lead to damage to DNA of the cancer cells, slowing their division, and pushing them toward their programmed death.
Consequently, they destroy themselves. Studies that have been done in cell lines, such as those from colon cancer, show that Pevonedistat effectively reduces the rapid growth of cells and may even stop the migration that lead to the spread of tumors.
The Potential Effect of Pevonedistat
This drug has been tested on different types of cancer in the lab, and it has been found to be effective on several of them. The following are a few examples:
Kidney Cancer: The drug did more than stop the growth of kidney cancer. It also made them less able to invade other parts of the body, keeping them in only one part. What this means is that the cells had less power to move around and spread to cause damage to other body parts.
Blood Cancers: There are different types of blood cancer, including acute myeloid leukemia. Pevonedistat was found to cause stress to the cancer cells by inhibiting the cleanup of damaged or ineffective proteins and causing their death. Some of these cancers depend a lot on how quickly protein can turn over, and this reliance on protein makes them especially vulnerable to this treatment.
Malignant Solid Tumors: The results for malignant solid tumors are not uniform. The reason for the varied results lies with how the different cell types interact with Pevonedistat; some are more sensitive than others. In other words, the drug may be more effective on some types of cancers and less effective in others. Click here to learn more about solid tumors.
Effect When Combined: Pevonedistat was found to work much better and more powerfully when it was paired with other cell stressors, such as the inflammatory signal called TNF-α. The combination took down cancer cells to the point of collapse because it hit them from different angles and left no room for survival or escape.
It is important to point out that the drug or combination of the drug and other molecules known to put stress on cells is not very selective of what it hits. This means that normal, healthy cells will be hit from time to time in the pursuit of cancer cells.
However, because of its design, Pevonedistat hits cancer cells harder than healthy ones because they are an abnormal occurrence. Normal ones do not fall apart under the pressure, but cancerous ones do.
The Promise Offered By Pevonedistat
There are several reasons this new drug excites the medical world, and below are some of them.
Effect on Cancer: The fact that these unhealthy cells depend on the neddylation process to grow and multiply makes them exceptionally vulnerable to Pevonedistat, more so than healthy ones.
Combination Effectiveness: When combined with other molecules or treatment methods that work well at stressing cancer cells, Pevonedistat tends to perform better than when it is alone. So, it does not isolate other drugs but joins forces to be more deadly for unusual cancerous cell growth.
Unique Targeting: The drug goes for the system that cleans up excess protein in the cells, instead of attacking the cancer, which is what other treatment options do. This is unusual but brilliant.
Broad Activity: It has been shown that Pevonedistat is effective on different types of cancers, including solid tumors and rare blood cancers. This versatility means it is dependable across multiple forms of the disease.
Note that Pevonedistat must be used in just the right dose to be effective. If the dose is too high, it may run amok and attack healthy cells in a way that makes it impossible for them to recover, and if the dose is too low, it will not be effective on the target.
There is also the possibility of it causing toxicity issues in the cells if the protein cleanup process is blocked by Pevonedistat. This can lead to tissue damage or worse health issues.
Conclusion
There is a lot of promise attached to Pevonedistat, and while it is still under clinical trials in some areas, its effect is more than many other treatments have shown in the past. Its brilliant method of attacking cancer, that is inhibiting the protein cleanup system and letting the proteins run wild to suffocate the cells, is unique and highly effective.
However, it is yet to have a good effect on all cancers, although it has shown promise in some blood cancers and solid tumors.